Quick Takeaways
- Lincoln Alternative Strategies LLC filed SCHEDULE 13G for Calidi Biotherapeutics, Inc. Common Stock, $0.0001 par value (CLDI).
- Disclosed ownership: 14%.
- Date of event: 20 Aug 2025.
Lincoln Alternative Strategies LLC - 20 Aug 2025 SCHEDULE 13G Report for Calidi Biotherapeutics, Inc. Common Stock, $0.0001 par value (CLDI)
- Filing Manager
- Lincoln Alternative Strategies LLC
- Reporting Manager
- Lincoln Alternative Strategies LLC
- Symbol
- CLDI
- Shares outstanding
- 5,048,409 shares
- Disclosed Ownership
- 730,000 shares
- Ownership
- 14%
- Form type
- SCHEDULE 13G
- Filing time
- 27 Aug 2025, 09:15:04 UTC
- Date of event
- 20 Aug 2025
- Next filing
- 10 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Lincoln Alternative Strategies LLC disclosed 14% ownership in Calidi Biotherapeutics, Inc. Common Stock, $0.0001 par value (CLDI) on 20 Aug 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 27 Aug 2025, 09:15.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Lincoln Alternative Strategies LLC | 14% | 730,000 | 730,000 | 0 | /s/ Stephen Temes | Stephen Temes/Managing Member |